CINGW
Cingulate Inc.
Set alert
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0385
- Prev close
- 0.0038
- Mkt cap
- 25.99K
- Vol
- 71.70K
- Avg vol
- 0
- EPS
- -1.73
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.003
- High
- 0.0039
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.01
- EPS (TTM)
- -1.73
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -10.79M
- Total cash
- 10.04M
- Total debt
- 234.17K
- Return on equity
- -273.82%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Cingulate Inc.
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cingulate.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on CINGW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Altium Capital Management, LP | 7.56% | 270,000 | 16.20K | Sep 29, 2024 |
| Hudson Bay Capital Management Lp | 5.90% | 210,798 | 12.65K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.55% | 19,479 | 1.17K | Sep 29, 2024 |
| UBS Group AG | 0.34% | 12,297 | 737 | Sep 29, 2024 |
| Virtu Financial LLC | 0.31% | 11,159 | 669 | Sep 29, 2024 |
| GoalVest Advisory, LLC | 0.08% | 3,000 | 179 | Sep 29, 2024 |